Related Experiment Video

Updated: Jun 17, 2026

Fluorescence-Based Quantification of Mitochondrial Membrane Potential and Superoxide Levels Using Live Imaging in HeLa Cells
06:57

Fluorescence-Based Quantification of Mitochondrial Membrane Potential and Superoxide Levels Using Live Imaging in HeLa Cells

Published on: May 12, 2023

Mutational analysis of parkin and PINK1 in multiple system atrophy

Janet A Brooks1, Henry Houlden, Anna Melchers

  • 1Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, 35 Convent Drive, Bethesda, MD 20892, USA.

Neurobiology of Aging
|December 26, 2009
PubMed

Insights

Genetic screening of Parkinson

Area of Science:

  • Neurodegenerative diseases
  • Genetics of neurodegeneration
  • Molecular pathogenesis

Background:

  • Multiple system atrophy (MSA) and Parkinson's disease (PD) are progressive neurodegenerative disorders.
  • These conditions share overlapping clinical, biochemical, and genetic features.
  • The role of specific Parkinson's disease genes in MSA pathogenesis is not fully understood.

Purpose of the Study:

  • To investigate the potential role of the Parkinson's disease genes parkin and PINK1 in the pathogenesis of Multiple system atrophy.
  • To screen for mutations and genetic variants in parkin and PINK1 in a cohort of pathologically confirmed MSA cases.

Main Methods:

  • A mutational screening study was conducted on 87 pathologically confirmed cases of Multiple system atrophy.
  • Sequence variants and deletions in the parkin gene were identified.
  • Sequence variants in the PINK1 gene were analyzed.

Main Results:

  • Eight sequence variants and four heterozygous deletions were found in the parkin gene.
  • Nine variants, including two novel silent mutations (p.Gly189Gly and p.Arg337Arg), were identified in the PINK1 gene.
  • The frequencies of these variants did not significantly differ from control data, and no pathogenic variants were found in a homozygous state.

Conclusions:

  • Genetic variants in the parkin and PINK1 genes do not appear to play a critical role in the pathogenesis of Multiple system atrophy.
  • The study suggests that other genetic or environmental factors may be more significant in MSA development.

More Related Videos

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease15:09

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease

Published on: October 3, 2012

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...